Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Left Ventricular Systolic Dysfunction Clear all
Recruiting Not applicable Interventional

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

NCT05427370
View directory record Official record
Conditions
Coronary Artery Disease, Heart Failure Systolic
Interventions
Revascularization by PCI, Revascularization by CABG
Procedure
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 4, 2026, 5:15 AM EDT
Completed Not applicable Interventional

ECG AI-Guided Screening for Low Ejection Fraction

NCT04000087
View directory record Official record
Conditions
Asymptomatic Left Ventricular Systolic Dysfunction (Disorder), Heart Failure
Interventions
AI-enabled ECG-based Screening Tool
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 4, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

NCT02970669
View directory record Official record
Conditions
Heart Failure, Reduced Ejection Fraction
Interventions
sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 4, 2026, 5:15 AM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085
View directory record Official record
Conditions
Heart Failure, Left Ventricular Systolic Dysfunction
Interventions
Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
29 Days to 17 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 5:15 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)

NCT01052428
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
metoprolol succinate (Toprol XL), Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Sep 4, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

NCT01786512
View directory record Official record
Conditions
Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram
Interventions
Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
38
States / cities
Mobile, Alabama • Costa Mesa, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 4, 2026, 5:15 AM EDT
Completed Phase 4 Interventional

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

NCT00082589
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
53
States / cities
Castro Valley, California • San Diego, California • Santa Rosa, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 4, 2026, 5:15 AM EDT
Not listed No phase listed Observational

SCD-HeFT 10 Year Follow-up

NCT01058837
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Congestive Heart Failure, Ischemic and Non-ischemic Cardiomyopathy, Sudden Cardiac Death Primary Prevention
Interventions
Not listed
Lead sponsor
Seattle Institute for Cardiac Research
Other
Eligibility
18 Years to 90 Years
Enrollment
1,855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Sep 4, 2026, 5:15 AM EDT
Completed No phase listed Observational

The Product Surveillance Registry REVERSE Post Approval Study

NCT01660035
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
102
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Sep 4, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

NCT00684060
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Sep 4, 2026, 5:15 AM EDT
Not listed No phase listed Observational

CarDiac MagnEtic Resonance for Primary Prevention Implantable CardioVerter DebrillAtor ThErapy: an International Registry (DERIVATE)

NCT03352648
View directory record Official record
Conditions
Heart Failure, Left Ventricular Systolic Dysfunction
Interventions
Not listed
Lead sponsor
Gianluca Pontone, MD, PhD
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 4, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

NCT00748579
View directory record Official record
Conditions
Heart Failure
Interventions
CK-1827452
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 4, 2026, 5:15 AM EDT
Completed No phase listed Observational

The Signal-averaged ElectrocArdiogram in Long Term Follow-up of Chronic CHagas Disease - RIO de Janeiro Cohort

NCT01340963
View directory record Official record
Conditions
Chagas Cardiomyopathy, Cardiac Arrhythmia, Stroke, Left Ventricular Function Systolic Dysfunction, Cardiac Death
Interventions
Not listed
Lead sponsor
Universidade Gama Filho
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Sep 4, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure

NCT02032004
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Rexlemestrocel-L, Sham Comparator
Biological · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
56
States / cities
Birmingham, Alabama • Gilbert, Arizona • Mesa, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 4, 2026, 5:15 AM EDT
Completed No phase listed Observational

Patient and Physician Survey Determinants of Appropriate ICD Utilization

NCT01514773
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Not listed
Lead sponsor
Todd M Koelling, MD
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 4, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)

NCT00271154
View directory record Official record
Conditions
Heart Failure
Interventions
Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
34
States / cities
Huntsville, Alabama • Anchorage, Alaska • Redwood City, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2012 · Synced Sep 4, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics

NCT01065051
View directory record Official record
Conditions
Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 4, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

NCT00414609
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Aliskiren, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Novartis US, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Sep 4, 2026, 5:15 AM EDT
Active, not recruiting No phase listed Observational

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

NCT05036252
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Cardiotoxicity
Interventions
Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 4, 2026, 5:15 AM EDT
Recruiting No phase listed Observational

Multimodality Evaluation of Left Ventricular Remodeling In Mitral Regurgitation: A Pilot Study

NCT06770062
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 4, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

NCT01300013
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Omecamtiv mecarbil
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Mobile, Alabama • Inglewood, California • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 4, 2026, 5:15 AM EDT
Withdrawn Phase 4 Interventional

Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.

NCT03392740
View directory record Official record
Conditions
Cardiomyopathy Due to Drug, Heart Failure, Systolic
Interventions
Lisinopril, Placebo Oral Tablet
Drug
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Sep 4, 2026, 5:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

NCT02678312
View directory record Official record
Conditions
Pediatric Heart Failure
Interventions
LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 4, 2026, 5:15 AM EDT
Completed No phase listed Observational Results available

IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting

NCT00303979
View directory record Official record
Conditions
Heart Failure, Congestive, Myocardial Infarction, Ventricular Dysfunction, Left
Interventions
Not listed
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
34,810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
144
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 121 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Sep 4, 2026, 5:15 AM EDT